(Reuters) – The U.S. Food and Drug Administration approved Jazz Pharmaceuticals Plc’s treatment for patients with a form of sleep disorder, the company said on Wednesday.
The drug, solriamfetol, will treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).
The decision is a big win for the drugmaker whose patents covering its blockbuster narcolepsy drug, Xyrem, was declared invalid by a U.S. appeals court in July.
Reporting by Aakash Jagadeesh Babu and Supriya Roy in Bengaluru; Editing by Richard Chang
Our Standards:The Thomson Reuters Trust Principles.
Source: Reuters.com
